These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A retrospective review of glargine use in pregnancy.
    Author: Henderson CE, Machupalli S, Marcano-Vasquez H, Kerr P, Reilly KD.
    Journal: J Reprod Med; 2009 Apr; 54(4):208-10. PubMed ID: 19438161.
    Abstract:
    OBJECTIVE: To review the obstetric outcome of 240 diabetic pregnancies maintained on basal glargine insulin. STUDY DESIGN: This is a retrospective review of the medical data from 240 pregnant diabetics who received glargine as a basal insulin. Perinatal outcome was abstracted from August 29, 2001, to December 31, 2007. RESULTS: Mean maternal age was 33 years (SD +/- 5). Seventy-seven percent (184 of 240) of the women were diagnosed with gestational diabetes. The remaining 23% (56 of 240) had a diagnosis of type 2 diabetes. Weekly evaluation of each woman's daily 7x/d fingersticks yielded an individual mean capillary glucose value. These individual mean capillary glucose values were used to calculate a mean value for our sample population. This overall mean capillary glucose value for the 240 parturients was 112 +/- 14.8 mg/dL. The mean neonatal birth weight was 3,142 +/- 606 g. Only 4 neonates had birth weights > 4,000 g (4,365, 4,384, 4,535 and 4,624). None of the neonates were hypoglycemic. CONCLUSION: Prenatal glargine appears to be well tolerated with acceptable perinatal outcome. For well-controlled pregestational diabetics, consideration should be given to continuing glargine during pregnancy.
    [Abstract] [Full Text] [Related] [New Search]